Multicenter randomized double-blind parallel-group add-on superiority study to

Recruiting

99 years or below

All

Phase 3

6 participants needed

1 Location

Brief description of study

This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these two drugs together in comparison to Tecfidera® alone (plus placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: ['Breast Cancer', 'Hereditary Breast/Ovarian Cancer (brca1, brca2)', 'Heart Diseases', 'Drug-Induced Cardiomyopathy']
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 828873

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Brief description of study

Eligibility of study

Find a site

Interested in the study